Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
41
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Fastly
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Price Cuts And Regulatory Hurdles Will Strangle Profitability
Key Takeaways Intensifying competition, client concentration, and regulatory challenges threaten Fastly's market share, pricing power, and revenue stability. High investment needs and operational costs in new areas may prevent sustainable profitability without faster adoption or improved expense management.
View narrative
US$6.00
FV
15.8% overvalued
intrinsic discount
5.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Xencor
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
IBD Competition Will Limit Pipeline Progress Despite Early Promise
Key Takeaways Increasing competition and pricing pressures threaten Xencor's revenue growth and long-term profitability despite innovative therapies and a strong pipeline. Dependence on successful clinical trials, prolonged development timelines, and tight funding conditions may create earnings volatility and risk to shareholder value.
View narrative
US$8.67
FV
11.4% undervalued
intrinsic discount
-7.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Coursera
AN
AnalystLowTarget
Consensus Narrative from 13 Analysts
Legal Barriers And AI Uncertainty Will Undermine Online Learning
Key Takeaways Declining willingness to pay and rising competition from free educational resources threaten Coursera's pricing power, revenue, and long-term profitability. AI-driven content obsolescence and increased regulatory hurdles are expected to raise costs, constrain international expansion, and pressure margins.
View narrative
US$9.08
FV
31.2% overvalued
intrinsic discount
4.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Immunocore Holdings
AN
AnalystLowTarget
Consensus Narrative from 15 Analysts
European Price Controls Will Erode Immunotherapy Viability
Key Takeaways Reliance on favorable drug pricing and a single lead product increases vulnerability to future regulatory and market shifts, risking income and growth stability. Escalating competition and regulatory hurdles threaten both technology relevance and clinical pipeline progress, undermining long-term commercial viability.
View narrative
US$24.93
FV
31.9% overvalued
intrinsic discount
2.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Sphere Entertainment
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Las Vegas Events Will Suffer With Digital Disruption
Key Takeaways Heavy reliance on large, capital-intensive venues makes Sphere Entertainment vulnerable to shifts in consumer entertainment preferences and broader economic uncertainty. Intensifying competition from digital and at-home technologies threatens the company's pricing power, event demand, and ability to sustain premium revenue streams.
View narrative
US$35.00
FV
13.9% overvalued
intrinsic discount
6.09%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
AMC Entertainment Holdings
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
Rising Streaming Dominance Will Erode Premium Theatre Appeal
Key Takeaways The shift to streaming, changing consumer habits, and reduced exclusive content access threaten AMC's ability to attract audiences and sustain revenue growth. High debt levels and financial constraints limit AMC's capacity for investment in innovation, increasing exposure to earnings volatility and competitive pressures.
View narrative
US$2.60
FV
15.4% overvalued
intrinsic discount
7.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
6855
Ascentage Pharma Group International
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Takeda Payments Will Undermine Revenue Amid China NRDL Pressures
Key Takeaways Over-reliance on non-recurring partnership payments and pipeline-stage products renders future revenue and earnings highly uncertain amidst rising competition and healthcare cost pressures. Intensifying regulatory, geopolitical, and funding challenges threaten global expansion, product launches, and long-term financial sustainability, exposing the company to dilution and operational cutbacks.
View narrative
HK$51.97
FV
65.7% overvalued
intrinsic discount
-3.83%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
InnoCare Pharma
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
Key Takeaways Heavy dependence on a single drug and regulatory risks threaten profitability and revenue stability, especially if late-stage trials or approvals face setbacks. Heightened cost pressures, geopolitical barriers, and aggressive R&D outlays could limit global expansion, compress margins, and suppress future earnings per share.
View narrative
HK$8.21
FV
138.8% overvalued
intrinsic discount
29.20%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Teladoc Health
AN
AnalystLowTarget
Consensus Narrative from 20 Analysts
Rising Global Regulations And Healthcare Pressures Will Lower Valuation
Key Takeaways Rising compliance and operational costs, alongside intensifying competition and reimbursement uncertainty, threaten Teladoc's margins and long-term profitability across core and emerging business segments. Limited digital infrastructure and healthcare access in key markets restrict addressable growth, despite greater virtual care adoption and expanded service offerings.
View narrative
US$7.00
FV
7.4% overvalued
intrinsic discount
-0.67%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Value any company in seconds
Popular companies